Disc Medicine to present Phase 3 trial results for bitopertin
WATERTOWN, Mass. - On October 19, 2026, Disc Medicine Inc. will hold a webcast to share the major findings from its APOLLO Phase 3 trial evaluating bitopertin for the treatment of erythropoietic protoporphyria. The event begins at 8:00 a.m. ET. A recorded version of the presentation will be posted on the company's website afterwards.
Bitopertin is a drug being developed to inhibit glycine transporter 1, aiming to alter heme biosynthesis. It is being investigated as a potential therapy for hematologic conditions, particularly erythropoietic porphyrias. Clinical studies, including the Phase 2 BEACON and AURORA trials, as well as the open-label HELIOS extension trial and the current Phase 3 APOLLO trial, have examined bitopertin's effectiveness in patients with erythropoietic protoporphyria.
Disc Medicine secured global licensing rights to bitopertin from Roche in May 2021. The Watertown-based company specializes in creating therapies for hematologic diseases by targeting heme biosynthesis and iron regulation.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
